The European Haemophilia Consortium (EHC) needs funds to pursue its mission on behalf of people with rare bleeding disorders.

The EHC’s National Member Organisations (NMOs) pay an annual membership fee, determined by the General Assembly.

The EHC receives external funding support from both public and private organisations. The EHC accepts financial and non-monetary support with the mutual understanding that the EHC maintains its independence and makes choices based exclusively on the needs and interests of patients. The EHC follows a strict Policy on Financial Support from Corporate Sponsors.

The EHC’s General Assembly meets every year and approves the organisations Annual and Financial Reports. The EHC’s accounts are also audited yearly and submitted to the Belgian commercial court for publication.

To read our latest Annual Report, click here. Our annual report also contains our most recent financial report.

The EHC gratefully acknowledges members of the EHC’s Corporate Giving Program (GCP) andRound Table (RT) Program:

CGP PLATINUM MEMBERS

  • Bayer
  • BioMarin
  • CSL Behring
  • Novo Nordisk
  • Pfizer
  • Roche
  • Takeda
  • Sobi

CGP GOLD MEMBERS

  • Sanofi Genzyme
  • Spark
  • UniQure

CGP SILVER MEMBERS

  • Biotest
  • Kedrion

RT PLATINUM SPONSORS

RT SILVER SPONSORS

  • Biotest
  • Roche